In situ monitoring of carbamazepine-nicotinamide cocrystal intrinsic dissolution behaviour

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 83, Issue 3, 2013, Pages 415-426

  Qiao, Ning ^a   Wang, Ke ^a   Schlindwein, Walkiria ^a   Davies, Angela ^a   Li, Mingzhong ^a  

^a DE MONTFORT UNIVERSITY   (United Kingdom)

Author keywords

Carbamazepine; Cocrystal; Intrinsic dissolution; Raman spectroscopy; UV imaging

Indexed keywords

CARBAMAZEPINE; NICOTINAMIDE;

ARTICLE; BIOTRANSFORMATION; CRYSTAL STRUCTURE; DRUG MONITORING; DRUG SOLUBILITY; INFRARED SPECTROSCOPY; PHASE TRANSITION; RAMAN SPECTROMETRY; SCANNING ELECTRON MICROSCOPY; THERMOGRAVIMETRY; ULTRAVIOLET SPECTROSCOPY;

ANTICONVULSANTS; CARBAMAZEPINE; CRYSTALLIZATION; MICROSCOPY, ELECTRON, SCANNING; NIACINAMIDE; SOLUBILITY; SPECTROPHOTOMETRY, ULTRAVIOLET; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SPECTRUM ANALYSIS, RAMAN; THERMOGRAVIMETRY; VITAMIN B COMPLEX;

EID: 84875215120     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2012.10.005     Document Type: Article

References (48)

1. N. Qiao, M. Li, W. Schlindwein, N. Malek, A. Davies, and G. Trappitt Pharmaceutical cocrystals: an overview Int. J. Pharm. 419 2011 1 11
2. C.B. Aakeröy, S. Forbes, and J. Desper Using cocrystals to systematically modulate aqueous solubility and melting behavior of an anticancer drug J. Am. Chem. Soc. 131 2009 17048 17049
3. S. Basavoju, D. Boström, and S. Velaga Indomethacin-saccharin cocrystal: design, synthesis and preliminary pharmaceutical characterization Pharm. Res. 25 2008 530 541
4. K. Shiraki, N. Takata, R. Takano, Y. Hayashi, and K. Terada Dissolution improvement and the mechanism of the improvement from cocrystallization of poorly water-soluble compounds Pharm. Res. 25 2008 2581 2592
5. H.G. Lee, G.G.Z. Zhang, and D.R. Flanagan Cocrystal intrinsic dissolution behavior using a rotating disk J. Pharm. Sci. 100 2011 1736 1744
6. D. McNamara, S. Childs, J. Giordano, A. Iarriccio, J. Cassidy, M. Shet, R. Mannion, E. O'Donnell, and A. Park Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API Pharm. Res. 23 2006 1888 1897
7. K. Greco, R. Bogner, Solution-mediated phase transformation: Significance during dissolution and implications for bioavailability, J. Pharm. Sci. (2011) n/a-n/a.
8. R.J. Davey, P.T. Cardew, D. McEwan, and D.E. Sadler Rate controlling processes in solvent-mediated phase transformations J. Cryst. Growth 79 1986 648 653
9. K. Greco, D.P. McNamara, and R. Bogner Solution-mediated phase transformation of salts during dissolution: investigation using haloperidol as a model drug J. Pharm. Sci. 100 2011 2755 2768
10. Y. Kobayashi, S. Ito, S. Itai, and K. Yamamoto Physicochemical properties and bioavailability of carbamazepine polymorphs and dihydrate Int. J. Pharm. 193 2000 137 146
11. C. Rustichelli, G. Gamberini, V. Ferioli, M.C. Gamberini, R. Ficarra, and S. Tommasini Solid-state study of polymorphic drugs: carbamazepine J. Pharm. Biomed. Anal. 23 2000 41 54
12. S. Šehić, G. Betz, Š. Hadžidedić, S.K. El-Arini, and H. Leuenberger Investigation of intrinsic dissolution behavior of different carbamazepine samples Int. J. Pharm. 386 2010 77 90
13. M. Ono, Y. Tozuka, T. Oguchi, S. Yamamura, and K. Yamamoto Effects of dehydration temperature on water vapor adsorption and dissolution behavior of carbamazepine Int. J. Pharm. 239 2002 1 12
14. F. Tian, N. Sandler, J. Aaltonen, C. Lang, D.J. Saville, K.C. Gordon, C.J. Strachan, J. Rantanen, and T. Rades Influence of polymorphic form, morphology, and excipient interactions on the dissolution of carbamazepine compacts J. Pharm. Sci. 96 2007 584 594
15. E. Laine, V. Tuominen, P. Ilvessalo, and P. Kahela Formation of dihydrate from carbamazepine anhydrate in aqueous conditions Int. J. Pharm. 20 1984 307 314
16. P. Kahela, R. Aaltonen, E. Lewing, M. Anttila, and E. Kristoffersson Pharmacokinetics and dissolution of two crystalline forms of carbamazepine Int. J. Pharm. 14 1983 103 112
17. N. Rodríguez-Hornedo, and D. Murphy Surfactant-facilitated crystallization of dihydrate carbamazepine during dissolution of anhydrous polymorph J. Pharm. Sci. 93 2004 449 460
18. H. Konno, T. Handa, D.E. Alonzo, and L.S. Taylor Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine Eur. J. Pharm. Biopharm. 70 2008 493 499
19. D. Alonzo, G. Zhang, D. Zhou, Y. Gao, and L. Taylor Understanding the behavior of amorphous pharmaceutical systems during dissolution Pharm. Res. 27 2010 608 618
20. D. Murphy, F. Rodríguez-Cintrón, B. Langevin, R.C. Kelly, and N. Rodríguez-Hornedo Solution-mediated phase transformation of anhydrous to dihydrate carbamazepine and the effect of lattice disorder Int. J. Pharm. 246 2002 121 134
21. J. Ulrich, A. Schuster, T. Stelzer, Crystalline coats or hollow crystals as tools for product design in pharmaceutical industry, Journal of Crystal Growth.
22. D. Martins, T. Stelzer, J. Ulrich, and G.r. Coquerel Formation of crystalline hollow whiskers as relics of organic dissipative structures Cryst. Growth Des. 11 2011 3020 3026
23. S.S. Dette, T. Stelzer, M.J. Jones, G. Coquerel, and J. Ulrich Fascinating control of crystalline microstructures Chem. Eng. Res. Des. 88 2010 1158 1162
24. N. Huang, and N. Rodríguez-Hornedo Engineering cocrystal solubility, stability, and pHmax by micellar solubilization J. Pharm. Sci. 100 2011 5219 5234
25. S.L. Childs, L.J. Chyall, J.T. Dunlap, V.N. Smolenskaya, B.C. Stahly, and G.P. Stahly Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids J. Am. Chem. Soc. 126 2004 13335 13342
26. J. Aaltonen, P. Heinänen, L. Peltonen, H. Kortejärvi, V.P. Tanninen, L. Christiansen, J. Hirvonen, J. Yliruusi, and J. Rantanen In situ measurement of solvent-mediated phase transformations during dissolution testing J. Pharm. Sci. 95 2006 2730 2737
27. P. Lehto, J. Aaltonen, M. Tenho, J. Rantanen, J. Hirvonen, V.P. Tanninen, and L. Peltonen Solvent-mediated solid phase transformations of carbamazepine: effects of simulated intestinal fluid and fasted state simulated intestinal fluid J. Pharm. Sci. 98 2009 985 996
28. J. van der Weerd, and S.G. Kazarian Combined approach of FTIR imaging and conventional dissolution tests applied to drug release J. Control. Release 98 2004 295 305
29. P. Lehto, J. Aaltonen, P. Niemelä, J. Rantanen, J. Hirvonen, V.P. Tanninen, and L. Peltonen Simultaneous measurement of liquid-phase and solid-phase transformation kinetics in rotating disc and channel flow cell dissolution devices Int. J. Pharm. 363 2008 66 72
30. 19F nuclear magnetic resonance spectroscopy and imaging studies of fluvastatin™ in Lescol® XL tablets in a USP-IV dissolution cell J. Control. Release 156 2011 345 354
31. J.P. Boetker, M. Savolainen, V. Koradia, F. Tian, T. Rades, A. Múllertz, C. Cornett, J. Rantanen, and J. Ostergaard Insights into the early dissolution events of amlodipine using UV imaging and raman spectroscopy Mol. Pharm. 8 2011 1372 1380
32. J. Østergaard, E. Meng-Lund, S. Larsen, C. Larsen, K. Petersson, J. Lenke, and H. Jensen Real-time UV imaging of nicotine release from transdermal patch Pharm. Res. 27 2010 2614 2623
33. J. Østergaard, F. Ye, J. Rantanen, A. Yaghmur, S.W. Larsen, C. Larsen, and H. Jensen Monitoring lidocaine single-crystal dissolution by ultraviolet imaging J. Pharm. Sci. 100 2011 3405 3410
34. F. Ye, A. Yaghmur, H. Jensen, S.W. Larsen, C. Larsen, and J. Ostergaard Real-time UV imaging of drug diffusion and release from Pluronic F127 hydrogels Eur. J. Pharm. Sci. 43 2011 236 243
35. M. Savolainen, K. Kogermann, A. Heinz, J. Aaltonen, L. Peltonen, C. Strachan, and J. Yliruusi Better understanding of dissolution behaviour of amorphous drugs by in situ solid-state analysis using Raman spectroscopy Eur. J. Pharm. Biopharm. 71 2009 71 79
36. F. Tian, J.A. Zeitler, C.J. Strachan, D.J. Saville, K.C. Gordon, and T. Rades Characterizing the conversion kinetics of carbamazepine polymorphs to the dihydrate in aqueous suspension using Raman spectroscopy J. Pharm. Biomed. Anal. 40 2006 271 280
37. M.C. Meyer, A.B. Straughn, E.J. Jarvi, G.C. Wood, F.R. Pelsor, and V.P. Shah The bioinequivalence of carbamazepine tablets with a history of clinical failures Pharm. Res. 9 1992 1612 1616
38. D.J. Berry, C.C. Seaton, W. Clegg, R.W. Harrington, S.J. Coles, P.N. Horton, M.B. Hursthouse, R. Storey, W. Jones, T. Friscic, and N. Blagden Applying hot-stage microscopy to co-crystal screening: a study of nicotinamide with seven active pharmaceutical ingredients Cryst. Growth Des. 8 2008 1697 1712
39. C. Lefebvre, A.M. Guyot-Hermann, M. Draguet-Brughmans, R. Bouché, and J.C. Guyot Polymorphic transitions of carbamazepine during grinding and compression Drug Dev. Ind. Pharm. 12 1986 1913 1927
40. D.J. Berry, C.C. Seaton, W. Clegg, R.W. Harrington, S.J. Coles, P.N. Horton, M.B. Hursthouse, R. Storey, W. Jones, T. Friscic, and N. Blagden Applying hot-stage microscopy to co-crystal screening: a study of nicotinamide with seven active pharmaceutical ingredients Cryst. Growth Des. 8 2008 1697 1712
41. L.E. McMahon, P. Timmins, A.C. Williams, and P. York Characterization of dihydrates prepared from carbamazepine polymorphs J. Pharm. Sci. 85 1996 1064 1069
42. S.G. Fleischman, S.S. Kuduva, J.A. McMahon, B. Moulton, R.D. Bailey Walsh, N. Rodríguez-Hornedo, and M.J. Zaworotko Crystal engineering of the composition of pharmaceutical phases: multiple-component crystalline solids involving carbamazepine Cryst. Growth Des. 3 2003 909 919
43. K. Seefeldt, J. Miller, F. Alvarez-Núñez, and N. Rodríguez-Hornedo Crystallization pathways and kinetics of carbamazepine-nicotinamide cocrystals from the amorphous state by in situ thermomicroscopy, spectroscopy, and calorimetry studies J. Pharm. Sci. 96 2007 1147 1158
44. N. Chieng, M. Hubert, D. Saville, T. Rades, and J. Aaltonen Formation kinetics and stability of carbamazepine-nicotinamide cocrystals prepared by mechanical activation Cryst. Growth Des. 9 2009 2377 2386
45. L.E. O'Brien, P. Timmins, A.C. Williams, and P. York Use of in situ FT-Raman spectroscopy to study the kinetics of the transformation of carbamazepine polymorphs J. Pharm. Biomed. Anal. 36 2004 335 340
46. C.J. Strachan, S.L. Howell, T. Rades, and K.C. Gordon A theoretical and spectroscopic study of carbamazepine polymorphs J. Raman Spectrosc. 35 2004 401 408
47. P.A. Anquetil, C.J.H. Brenan, C. Marcolli, and I.W. Hunter Laser Raman spectroscopic analysis of polymorphic forms in microliter fluid volumes J. Pharm. Sci. 92 2003 149 160
48. V.G. Levich Physicochemical Hydrodynamics 1962 Prentice-Hall Englewood Cliffs, NJ